Drug intelligence / Profile preview

Sugalife-S

Development stage: Preclinical
Lead developer: Intra Life
Modality: Small Molecules
Administration: Oral

Overview

**Sugalife-S** is an oral fixed-dose antidiabetic tablet marketed by Intra Life for **type 2 diabetes mellitus in adults**. It combines sustained-release gliclazide 60 mg, a sulfonylurea that promotes pancreatic beta-cell insulin secretion through ATP-sensitive potassium-channel closure, with sitagliptin 100 mg, a dipeptidyl peptidase-4 inhibitor that prolongs incretin activity to increase glucose-dependent insulin secretion and suppress glucagon. The product is intended to improve glycemic control when diet, exercise, or monotherapy are insufficient.

Brand names: Sugalife-S
Other names: gliclazide + sitagliptin

Targets

KATP channel (ATP-sensitive potassium channel)DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on Sugalife-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sugalife-S.

Explore the full profile